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Background: Cachexia may occur in 40% of cancer patients, representing the major cause of death in more than
20% of them. The aim of this study was to investigate the role of leptin, ghrelin and obestatin as diagnostic and
predictive markers of cachexia in oncologic patients. Their impact on patient survival was also evaluated.
Methods: 140 adults with different cancer diagnoses were recruited. Thirty healthy volunteers served as control.
Serum ghrelin, obestatin and leptin were tested at baseline and after a follow-up period of 18 months.
Results: Ghrelin levels were significantly higher in cancer patients than in healthy subjects (573.31 ± 130 vs
320.20 ± 66.48 ng/ml, p < 0.0001), while obestatin (17.42 ± 7.12 vs 24.89 ± 5.54 ng/ml, p < 0.0001) and leptin
(38.4 ± 21.2 vs 76.28 ± 17.48 ng/ml, p < 0.0001) values were lower. At ROC analyses the diagnostic profile of ghrelin
(AUC 0.962; sensitivity 83%; specificity 98%), obestatin (AUC 0.798; sensitivity 74.5%; specificity 81.5%) and leptin
(AUC 0.828; sensitivity 79%; specificity 73%) was superior to that of albumin (AUC 0.547; sensitivity 63%, specificity
69.4%) for detecting cachexia among cancer patients. On Cox multivariate analyses ghrelin (HR 1.02; 95% CI 1.01 – 1.03;
p < 0.0001) and leptin (HR 0.94; 95% CI 0.92 – 0.96; p < 0.0001) were significant predictors of death even after correction
for other known risk factors such as presence of metastasis and chronic kidney disease.
Conclusion: Ghrelin and leptin are promising biomarkers to diagnose cachexia and to predict survival in cancer
patients.
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Weight loss is commonly observed in several types of can-
cer, and poor nutritional status has been associated with
decreased survival and poorer quality of life in the cancer
population [1-3].
Cachexia may occur in 15% to 40% of patients with
cancer and in about 80% of patients with advanced illness,
representing the major cause of death in more than 20%
of patients [4,5].
According to a consensus panel, cachexia should be
diagnosed when, in the presence of an underlying disease,
there is a weight loss of at least 5% in 12 months or less
associated with any 3 of the following criteria: decreased
muscle strength, fatigue, anorexia, low fat-free mass index,* Correspondence: patriziamondello@hotmail.it
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unless otherwise stated.increased inflammatory markers such as C Reactive Protein
(CRP >5.0 mg/L) or interleukin (IL)-6 (>4.0 pg/ml), anemia
(Hb <12 g/dl) or low serum albumin (<3.2 g/dl) [6].
To date, even though clinical practice guidelines are
available [7-9] and provide recommendations for preven-
tion and treatment of cancer-related anorexia cachexia
syndrome (CACS), the management of CACS is still a
complex challenge. Biomarkers that can accurately diag-
nose CACS in the early stage and predict progression and
outcome would have important implications for develop-
ing the most effective interventions.
Food intake and energy homeostasis are regulated by a
complex network of peripheral mediators, such as hor-
mones, neuropeptides, and cytokines. In particular, in-
flammatory cytokines and other hormonal factors have
been postulated to play a role in the development of
cachexia [10,11]. Therefore previous studies have evalu-
ated the utility of albumin and prealbumin as markersral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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shown low sensitivity and specificity [12-15].
Similarly, high levels of inflammatory markers and low
hemoglobin value, which are usually associated with in-
creased mortality, do not significantly improve the ability
to predict survival better than cancer stage, albumin,
and weight loss [12,16].
Leptin, primarily produced by adipocytes in proportion
to body fat, has been postulated to play a major role in the
pathophysiology of cancer cachexia [17]. Decreased levels
of leptin have been demonstrated in cancer patients with
cachexia compared to those without cachexia and healthy
controls [18].
Ghrelin and obestatin, two gastrointestinal peptides
obtained by post-translational processing of preproghrelin,
are part of a complex gut-brain network informing the
brain about satiety or hunger [19]. Plasma ghrelin levels
are generally inversely related to body mass index (BMI).
Neary et al. demonstrated that the administration of ghrelin
in cancer patients with severe anorexia resulted in a marked
increase in both food consumption and energy intake
compared to controls [20]. Conversely, obestatin appears
to act as an anorectic hormone, decreasing food intake
and reducing body weight gain [21,22]. Obestatin showed
to be correlated positively with ghrelin and negatively with
BMI [23], insulin [24] and serum level of vasopressin [25].
This suggests that basal secretions of obestatin and ghrelin
may be regulated in a similar manner, since they are both
influenced by adiposity and insulin resistance [26].
Based on previous research and because of the evidence
of the important role played in the homeostasis of body
weight regulation, we hypothesized that leptin, ghrelin
and obestatin could be useful as diagnostic markers of
cachexia in oncologic patients. We also evaluated their
relation to patient survival.
Methods
Patients and controls
Between February 2010 and January 2011, we prospect-
ively enrolled 140 adult oncologic patients (74 men: mean
age 57.7 ± 11.3 years; 66 women, mean age: 60.6 ± 12 years)
admitted to the oncology unit of the University Hospital
“G. Martino”, Messina, Italy.
Exclusion criteria were: physician-recorded diagnosis of
formally evaluated dysphagia (by speech pathologist otolar-
yngologists), illicit drug or alcohol abuse, severe congestive
heart failure (defined as New York Heart Association
(NYHA) class III or IV), abnormal liver function, severe
chronic obstructive pulmonary disease, uncontrolled dia-
betes (fasting glucose levels of >140 mg/dL or random
glucose levels of >200 mg/dL), thyroid disease (defined
as abnormal levels of thyroid hormone levels causing hypo-
or hyperthyroidism condition), severe kidney disease(defined as glomerular filtration rate <15 ml/min), active
infection, history of neuroendocrine tumor, diagnosed
eating disorders or use of orexigenic agents (e.g., chronic
use of glucocorticoids, progesterone, testosterone, and
antiandrogens).
Diagnosis of cachexia follows the definition reported by
Evans [6]. In particular we considered as cachexia the pres-
ence of a weight loss of at least 5% or more in 12 months
or less, plus BMI <20, fatigue, abnormal biochemistry
(increased inflammatory markers: CRP >5.0 mg/L), anemia
(<12 g/dL) condition and low serum albumin (<3.2 g/dL).
Demographic and other data regarding the type of cancer
and cachexia diagnosis, cancer stage, treatment, comorbid-
ity, were also recorded. To assess percentage of weight
change, patients’ body weight was evaluated at enroll-
ment (baseline) and at 18 months. If the subject died be-
fore the end of follow up, the last weight recorded was
used to calculate the percent of weight change. Common
biochemical parameters including urea, creatinine, uric
acid, serum lipids, total serum calcium, phosphorus,
calcium-phosphate product, serum iron, electrolytes,
albumin, hemoglobin, total alkaline phosphatases and
fibrinogen were measured at baseline in all patients
and controls. Survival was determined at 18 months.
As a control group, 30 healthy volunteers without clinical
history of cancer and cardiovascular or metabolic diseases
were recruited.
The study was approved by the Province of Messina
Ethics Committee and fully informed consent was obtained
in writing from all participants.
Collection of blood and Ghrelin, obestatin and leptin
dosage
In the patient group and in the healthy control group
blood samples were collected at 08:00 h after an overnight
fast.
Blood samples were collected into chilled vacutainer
tubes containing potassium ethylenediamine tetracetate.
Tubes were instantly cooled on ice and centrifuged at
3000 rpm for 10 min at 4°C within 30 min, and aliquots
were immediately stored at −80°C until analyzed.
Serum ghrelin, obestatin and leptin were tested using an
enzyme-linked immunosorbent assay (ELISA) commercial
available kit (Obestatin: Bachem Distribution Services
GmbH, Weil am Rhein, Germany; Leptin: R&D Systems
Space Import-Export srl Milan, Italy; Ghrelin: Phoenix
Europe GmbH, Germany) according to the manufacturer’s
instructions. The enzymatic reactions were quantified in
an automatic microplate photometer.
Statistical analysis
Statistical analyses were performed with NCSS for
Windows (version 4.0), the MedCalc (version 11.0;
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and the GraphPad Prism (version 5.0; GraphPad Software,
Inc., San Diego, CA, USA) package. Data were pre-
sented as mean ± SD for normally distributed values (at
Kolmogorov-Smirnov test) and median [IQ range] for
non-normally distributed values. Differences between
groups were established by unpaired t test for normally
distributed values and by Kruskal-Wallis analysis followed
by Dunn’s test for nonparametric values. Dichotomized
values were compared using the x2 test. Receiver operat-
ing characteristics (ROC) analysis was employed to calcu-
late the area under the curve (AUC) for ghrelin, obestatin,
leptin and albumin and to find the best cut-off values able
to identify the presence of cachexia.
Survival analyses used the Kaplan–Meier survival curve
and the Cox proportional hazards model. Adjusted risk
estimates for survival were calculated using univariate
followed by multivariate Cox proportional hazard regres-
sion analysis. Exploratory graphical analysis and test of spe-
cific violations indicated no departure from the assumption
of proportional hazards. All results were considered sig-
nificant if p was <0.05.
Results
Study population
Demographic, clinical and laboratory data for controls
and cancer patients are shown in Table 1. Patients and
controls were well matched with regard to demographic
characteristics. 28 patients were diabetic (20%) with good
glycemic control (HbA1c 5.3 ± 1.6%). 37% of all patientsTable 1 Baseline demographic, clinical and laboratory data o
Parameters Cancer group HS group
n:140 n: 30
Age, y 61.8 ± 14.3 59.6 ± 12.2
Weight change, % 12.1 ± 8.9 -
Tot cholesterol (mg/dL) 142.9 ± 27.2 175.6 ± 12.
Diabetics, n 28 (20%) -
Hypertension, n 52 (37%) -
Heart Failure, n 16 (11%) -
CKD, n 56 (40%) -
Hemoglobin, g/dl 10.1 ± 2.5 13.6 ± 1.7
Metastatic disease, n 105 (75%) -
Albumin, g/L 2.7 ± 0.6 4.02 ± 0.8
Obestatin, ng/ml 17.4 ± 7.1 24.8 ± 5.5
Leptin, ng/ml 38.4 ± 21.2 76.2 ± 17.4
Ghrelin ng/ml 573.3 ± 130 320.2 ± 66.
P values calculated by using the t test, except where indicated.
*Calculated by using x2 test.
Abbreviations: HS healthy subjects, CKD chronic kidney disease, defined as glomerulwere hypertensive, 16% had mild congestive heart failure
(NYHA class I and II) and 56% had a chronic kidney
disease. 105 patients (75%) were in the most advanced
stage of cancer disease (namely stage IV according to
the TNM and Ann Arbor staging systems for solid tu-
mors and lymphomas respectively and stage III accord-
ing to the International Staging System for multiple
myeloma), whereas 35 (25%) belonged to stage III.
Enrolled patients were treated with one (28%) or more
(61%) chemotherapy lines and/or surgery treatment (21%)
and/or radiotherapy irradiations (17%). Oncologic and
treatment characteristics of the 140 patients included
in this study are summarized in Table 2.
Serum concentration of Ghrelin, obestatin and leptin
Ghrelin levels were significantly higher in cancer patients
than in healthy subjects (HS) (573.31 ± 130 versus 320.20 ±
66.48 ng/ml, p <0.0001), while levels of obestatin and leptin
were significantly lower (obestatin, 17.42 ± 7.12 versus
24.89 ± 5.54 ng/ml, p <0.0001; leptin, 38.4 ± 21.2 versus
76.28 ± 17.48 ng/ml, p <0.0001).
Accordingly with cancer stages, patients in stage IV
showed the highest ghrelin levels (683.5 ± 73.4 ng/ml),
the lowest leptin (19.67 ± 11.5 ng/ml) and obestatin
values (9.2 ± 4.1 ng/ml) with respect to stage III. How-
ever, no differences in these three hormone levels were
found to be related to the tumor burden, defined as
number of metastatic sites. In particular, ghrelin levels
observed in patients with one metastatic lesion (568.3 ±
51.2 ng/ml) were not statistically different from valuesf the study population
Follow up (18 months)
Death Survivors P
n:94 (67%) n:46 (33%)
67.4 ± 6.3 60.7 ± 8.9 0.01
18.6 ± 1.8 7.6 ± 2.3 < 0.0001





9.3 ± 1.6 10.8 ± 1.8 < 0.0001
90 15 <0.0001*
2.3 ± 0.4 2.5 ± 0.5 0.004
12.3 ± 2 15.1 ± 4.8 0.005
21.8 ± 10 33.8 ± 9.1 < 0.0001
8 657.6 ± 88 481.4 ± 43.6 < 0.0001
ar filtration rate <60 ml/min.
Table 2 Oncologic characteristics and chemotherapy drugs used
Cancer type, n (%) Surgery, n 30 (21) Radiotherapy, n 25 (17) Chemotherapy, n 129 (92)
Gastrointestinal cancer 27 (20%) 11 (37) 4 (16) 26 (21)
Lung and pleura cancer 25 (18%) 3 (10) 1 (4) 25 (19)
Pancreas cancer 3 (2%) 1 (3) - 2 (1)
Breast cancer 20 (14%) 9 (30) 9 (36) 18 (14)
Multiple Myeloma 13 (9%) - 5 (20) 12 (9)
Lymphomas 28 (20%) - 4 (16) 25 (19)
Head and Neck cancer 16 (11%) 1 (3) 2 (8) 15 (12)
Gynecologic cancer 8 (6%) 5 (17) - 7 (5)
Cancer Stage Patients, n (%) Death, n (%) Survival, n (%)
III* 35 (25) 4 (5 31 (68%)
III**- IV* 105 (75) 90 (95%) 15 (32%)
Chemotherapy drugs
Platinum 59 (42) 48 (81%) 11 (9%)
Anthracyclines 55 (39) 33 (60%) 22 (40%)
Taxanes 16 (12) 6 (37%) 10 (63%)
Anti-metabolites 75 (53) 57 (76%) 18 (24%)
Alkylating Agents 18 (13) 9 (50%) 9 (50%)
Vinca Alkaloids 16 (11) 7 (43%) 9 (57%)
Monoclonal Antibodies 24 (17) 13 (54%) 11 (46%)
Hormone therapy 12 (9) 6 (50%) 6 (50%)
*This stage refers to patients with solid tumors and lymphomas according to the TNM and Ann Arbor staging systems respectively.
**This stage refers to patients with multiple myeloma according to the International Staging System (ISS).
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sites (556 ± 108.47 ng/ml; p:0.82).
Univariate correlations
At univariate analysis, obestatin concentrations were posi-
tively correlated with leptin (r = 0.47; p <0.0001; Figure 1)
age (r = 0.19 ; p = 0.01 ), heart failure (r =0.30; p = 0.003),
and presence of metastasis (r = 0.39; p = 0.002), whereas
a negative correlation with ghrelin (r = -0.59; p <0.0001;
Figure 1), cholesterol (r = -0.45; p <0.0001), diabetes melli-
tus (r = -0.26; p = 0.002) and albumin (r = -0.21; p = 0.03)
was found.
Ghrelin correlated positively with cholesterol (r 0.29;
p = 0.004) and diabetes mellitus (r =0.17; p =0.03), and
negatively with obestatin (r = -0.59; p <0.0001), leptin
(r = -0.75; p <0.0001; Figure 1), heart failure (r = -0.25;
p = 0.001), presence of metastasis (r = -0.35; p <0.0001)
and serum protein levels (r = -0.33; p =0.0001).
Leptin concentrations were positively correlated with
obestatin (r = 0.47; p <0.0001), presence of metastasis
(r = 0.34; p <0.0001), and serum protein levels (r = 0.23;
p = 0.01) whereas a significant inverse correlation was
found with ghrelin (r = -0.75, p <0.0001), albumin (r = -0.27;
p = 0.004; Figure 1) and cholesterol (r = -0.28; p = 0.006).
Univariate relationships between leptin, obestatin, ghrelin
and albumin are summarized in Figure 1.Multiple regression analysis
All variables found to be significantly correlated with obes-
tatin at univariate analysis were introduced in a multivariate
model using obestatin as the dependent variable. After ad-
justment for other factors, only the correlations between
obestatin and albumin (β = -0.65; p = 0.0003), cholesterol
(β = - 0.48; p = 0.004), age (β = 0.23; p = 0.0007) and metas-
tasis (β = 0.47; p = 0.03) remained significant.
After adjustment for other factors, using ghrelin as
dependent variable, only the correlation between ghrelin
and cholesterol (β = 0.32; p = 0.02), and metastasis
(β = - 0.43 ; p = <0.0001) attained significance.
Analyzing leptin as dependent variable in a multivariate
model, significant correlation was maintained only between
leptin and metastasis (β = 0.40; p <0.001).
Diagnostic profile of obestatin, leptin and Ghrelin as
biomarkers of cachexia
ROC analyses were performed in order to define the
diagnostic profile of obestatin, leptin and ghrelin in iden-
tifying cachexia among cancer patients.
The area under the ROC curve for ghrelin, obestatin
and leptin were 0.962, 0.798 and 0.828, respectively. Best
cut-off values for ghrelin, obestatin and leptin were 663
(sensitivity 83%; specificity 98%), 13 (sensitivity 74.5%;
specificity 81.5%) and 31 ng/ml (sensitivity 79%; specificity
Figure 1 Univariate relationships between ghrelin & obestatin and ghrelin & leptin.
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bumin was very poor (AUC 0.547; best cut-off value of
2.9 g/dl; sensitivity 63%, specificity 69.4%). AUC of ghrelin
was statistically different compared with that of obestatin
(p <0.001), leptin (p =0.003) and albumin (p <0.001).
Obestatin and leptin areas were statistically different com-
pared with that of albumin (p = 0.03; p = 0.003, respect-
ively). On the contrary, there were no differences between
obestatin and leptin areas (p >0.05) Figure 2.Figure 2 Receiver operating characteristics (ROC) curves. ROC
curves of ghrelin, leptin, obestatin and albumin in oncological
subjects with cachexia.Ghrelin, leptin and obestatin: survival prediction
Biomarkers of cachexia were tested by Kaplan Meier
analysis, alone or in combination, with respect to all
cause-mortality during a median follow-up period of
18 months. During this period, 94 (67%) deaths occurred.
Kaplan–Meier analysis showed that patients with ghrelin
levels above the optimal ROC-derived cut-off value had a
poorer survival (log-rank (χ2): 5.02; p = 0.02), as well as
those with leptin values below 31 ng/ml (log-rank (χ2):
3.24; p = 0.03) and obestatin values below 13 ng/ml (log-
rank (χ2): 2.86; p = 0.03) with a mean follow-up time of
16 months and 17 months respectively (Figure 3A).
High levels of ghrelin and low leptin values were associ-
ated with minor survival probability with respect to those
observed in patients characterized by high levels of ghrelin
and low values of albumin. (log-rank (x 2) 8.02; p = 0.004).
On the contrary, patients with the best profile were those
with low levels of ghrelin associated with high levels either
of albumin or leptin, without any statistical differencebetween these two combinations (log-rank (χ2): 2.60;
p = 0.10) Figure 3B.Univariate/multiple Cox regression analysis
To identify putative risk factors associated with all-cause
mortality we performed a Cox regression analysis by
Figure 3 Kaplan–Meier all-cause mortality curves. A Kaplan-Meier survival curves of end-point (mortality during a median follow-up period of
18 months) in patients with ghrelin, leptin, albumin and obestatin levels above and below the optimal receiver operating characteristics cut-off
level. Patients with ghrelin >663 ng/ml showed a significantly faster progression to endpoint (log-rank (χ2) 5.02; p = 0.02) B Association of ghrelin,
leptin or albumin to provide the best predictive model of mortality. Patients with high levels of ghrelin and low leptin levels were characterized
by the worst outcome (log-rank (χ2) 8.02; p = 0.004). Patients with low levels of ghrelin and high levels of albumin instead had the best profile,
although there were no statistically significant differences if compared with patients with low levels of ghrelin and high levels.
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at baseline between survivors and non-survivors Table 1.
At univariate analysis, only ghrelin (HR 1.01; 95% CI
1.00 – 1.01; x2: 2.87; p 0.005), obestatin (HR 1.13; 95 CI
1.03 – 1.24; x2: 3.71; p 0.009), leptin (HR 0.92; 95% CI
0.88 – 0.95; x2: 5.36; p 0.0006), the presence of metastatic
lesions (HR 1.15; 95% CI 1.25 – 8.02; x2: 2.12; p 0.01) and
chronic kidney disease (HR 2.19; 95% CI 1.11 – 4.34; x2:
2.37; p 0.02) were significantly associated with the end-
point, whereas body weight decrease, hemoglobin, albu-
min and age failed to reach statistical significance.
In a multiple Cox regression model, all the variables
found to be significantly associated with the endpoint at
univariate analysis (ghrelin, obestatin, leptin, metastatic
disease and chronic kidney disease) were tested to identify
independent predictors (Figure 4). In addition, age was
also inserted in this model as it commonly represents one
of the most important risk factors for death.
Results from this analysis indicated that ghrelin (HR
1.02; 95% CI 1.01 – 1.03; x2: 5.81; p < 0.0001), leptin (HR
0.94; 95% CI 0.92 – 0.96; x2: 4.65; p 0.0001), the presence
of metastatic disease (HR 2.67; 95% CI 1.45 – 4.91; x2:3.86; p 0.001) and chronic kidney disease (HR 1.97; 95%
CI 1.24 – 3.12; x2: 2.14; p 0.003), remained significantly as-
sociated with mortality.
Table 3 summarizes data from univariate and multivari-
ate Cox regression analysis.
Discussion
We demonstrated that ghrelin and leptin represent prom-
ising biomarkers for the identification of cachexia associ-
ated with cancer.
In accordance with previous observations [27], we found
that ghrelin levels were higher in the cachexia group com-
pared to the control group. The increased concentration
of ghrelin in oncologic patients may represent a compen-
satory mechanism for catabolic-anabolic imbalance, which
is unable to reverse despite suppression of food intake and
muscle wasting [28]. We also found a strict inverse correl-
ation between ghrelin and heart disease, confirming the
existing data on the cardio-protective role of this hormone
[29]. In addition, ghrelin was correlated with the presence
of diabetes mellitus. Previous studies showed that ghrelin
exerts modulatory action on insulin secretion and glucose
Figure 4 Cox proportional hazard regression models including the effects of different variables on survival. CKD: chronic kidney disease.
Weight change was measured from baseline to 18 months follow-up.
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ghrelin and insulin [31,32].
Our oncologic patients were also characterized by lower
levels of leptin and obestatin. Mantovani et al have already
showed that circulating leptin concentrations are lower in
anorectic cancer patients than in healthy individuals [17].
Proinflammatory cytokines, such as TNF-α, IL-1, and
IL-6, have been proposed to cause cachexia despite low
circulating leptin, due to the increased expression of the
hypothalamic leptin receptor [33]. This deregulation ofTable 3 Univariate and multivariate Cox proportional hazards
Univariate analysis
HR 95% CI x2 p
Leptin 0.92 0.88 – 0.95 5.36 0.
Ghrelin 1.01 1.00 – 1.01 2.87 0
Obestatin 1.13 1.03 – 1.24 3.71 0
Albumin 1.66 0.81 – 3.40 1.23 0
CKD 2.19 1.11 – 4.34 2.37 0
Metastasis 1.15 1.25 – 8.02 2.12 0
Age 1.00 0.95 – 1.04 0.16 0
Weight change 0.90 0.82 – 1.00 0.27 0
Hemoglobin 0.99 0.86 – 1.15 0.12 0
HR: hazard ratio; CI: confidence interval; CKD: chronic kidney disease.
Weight change was measured from baseline to 18 months follow-up.the physiological feedback may explain why a decrease
in leptin does not increase appetite or lower energy ex-
penditure in patients with cancer cachexia. There are
several in vitro data on obestatin involvement in the on-
cologic field [21]. Different studies have shown that
obestatin has a role in regulating the cell cycle by exert-
ing proliferative effects through the inhibition of cell
proliferation markers or by mitogen-activated kinase/
extracellular signal-regulated kinases1/2 (ERK1/2) phos-
phorylation. Moreover, anti-proliferative effects have beenregression model for death
Multivariate analysis p value
value HR 95% CI x2
0006 0.94 0.92 – 0.96 4.65 0.0001
.005 1.02 1.01 – 1.03 5.81 < 0.0001
.009 1.04 0.99 – 1.10 1.05 0.10
.16
.02 1.97 1.24 – 3.12 2.14 0.003
.01 2.67 1.45 – 4.91 3.86 0.001
.95 1.00 0.95 – 1.01 0.15 0.93
.90
.97
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study in which obestatin has been related to cancer dis-
ease in humans. Our data confirmed that this hormone
plays an antithetic role with ghrelin in energy balance,
as demonstrated by the low levels of obestatin opposed
to the high levels of ghrelin. The relationship between
obestatin, cardiac dysfunction and diabetes might con-
firm its protective role on the cardiovascular system and
the negative influence on metabolic control [34,35].
Moreover, we found an independent correlation between
ghrelin, obestatin, leptin and severity of cancer disease in
our patients.
We have also shown that these three hormones hold a
high diagnostic sensitivity and specificity for detecting
cachexia in cancer patients. The hypothesis that nutrition-
related variables predict survival was supported by our re-
sults. In particular, patients with higher ghrelin levels had
a worse all-cause mortality, but if we consider the associa-
tions of the three biomarkers, patients with higher levels
of ghrelin and lower leptin values were characterized by
the worst outcome. We analyzed the effect of all variables
that were different at baseline on survival. Ghrelin and
leptin remained significant predictors of death independ-
ently of other potential confounders, such as the presence
of metastasis or chronic kidney disease.
Our results support the inclusion of ghrelin and leptin
among those factors able to influence survival in cancer
patients. Furthermore, this study included non-terminally
ill patients; this indicates that assessing these variables
might also be useful in the non-terminal cancer population.
This study has a major limitation represented by the
high heterogeneity of neoplasias and the severity of dis-
ease in patients enrolled in the study. Although ghrelin
and leptin were strongly associated with survival in the
whole study cohort, this heterogeneity could potentially
hamper the reliability of these results. Moreover, it is
possible that hormone levels could be influenced by
chemotherapy.
Conclusion
Our data suggest that simple and inexpensive testing may
be helpful to assess an oncology patient’s long-term risk
of mortality. Calculations of body weight change and
the evaluation of emerging biomarkers of nutritional
status may give the clinician a more accurate picture of
the patient’s prognosis. Further prospective studies are
necessary to confirm the potential application of these
hormones and to ascertain their relevance as a param-
eter for monitoring the development of CACS and the
progression of cancer disease.
In conclusion, there is a need to understand and explore
the role of various neuropeptides and cytokines in the
pathophysiology of cancer-anorexia syndrome so thattherapeutic measures, such as ghrelin administration,
may be designed to improve the survival of oncologic
patients.
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